Vimarsana
Biggest News Aggregation in the World

Page 42 - Webcast Information News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Webcast Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Webcast Information Today - Breaking & Trending Today

Yunhong CTI Ltd. to Host First Quarter 2023 Conference Call on April ... - Vimarsana News

Yunhong CTI Ltd. to Host First Quarter 2023 Conference Call on April ...

Yunhong CTI Ltd. to Host First Quarter 2023 Conference Call on April ...

Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting - Vimarsana News

Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting

● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft models with favorable pharmacokinetic and safety profiles● ZW171 induced potent preferential... | April 18, 2023

Remitly to Report First Quarter 2023 Financial Results on Wednesday, May 3, 2023 - Vimarsana News

Remitly to Report First Quarter 2023 Financial Results on Wednesday, May 3, 2023

SEATTLE, April 17, 2023 -- Remitly Global, Inc. , a leading digital financial services provider for immigrants and their families, today announced that it will report first quarter 2023 financial... | April 17, 2023

Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update - Vimarsana News

Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update

- Robust 36% overall response rate in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with... | April 14, 2023

Merus N.V.: Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Upda - Vimarsana News

Merus N.V.: Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Upda

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting